Clicky

Oramed Pharmaceuticals Inc.(ORMP)

Description: Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.


Keywords: Medicine Pharmaceutical Medication Diabetes Tablet Peptides Insulin Gastrointestinal Endocrine System Peptide Hormones Polyp Treatment Of Diabetes Glucagon Like Peptide 1 Pharmaceutical Solutions Integrated Security

Home Page: www.oramed.com

ORMP Technical Analysis

1185 Avenue of the Americas
New York, NY 10036
United States
Phone: 844 967 2633


Officers

Name Title
Mr. Nadav Kidron Esq. Pres, CEO & Exec. Chairman
Mr. David Silberman CPA CFO & Treasurer
Mr. Joshua Hexter Chief Operating & Bus. Officer
Dr. Miriam Kidron Ph.D. Chief Scientific Officer & Director
Mr. Michael Rabinowitz Chief Commercial Officer
Mr. Netanel Derovan Chief Legal Officer & Company Sec.
Dr. Roy Eldor M.D., Ph.D. Chief Medical Advisor & Member of the Scientific Advisory Board

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.0879
Price-to-Sales TTM: 117.9787
IPO Date: 2006-04-21
Fiscal Year End: August
Full Time Employees: 0
Back to stocks